Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | GSK3B | P49841 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1304505 | 0.84 | RAB9A (0.64) | NPC1RAB9ASMN1; SMN2GSK3BMEN1 | |
| SCHEMBL6201900 | 0.84 | RAB9A (0.59) | NPC1RAB9ASMN1; SMN2MAPTGAA | |
| SCHEMBL28872876 | 0.84 | PKM (0.62) | NPC1RAB9ASMN1; SMN2GSK3BMEN1 | |
| SCHEMBL668743 | 0.84 | NPC1 (0.63) | NPC1RAB9ASMN1; SMN2GSK3BMEN1 | |
| SCHEMBL199347 | 0.83 | CRHBP (0.62) | NPC1RAB9ASMN1; SMN2GSK3BMEN1 | |
| SCHEMBL4319309 | 0.83 | CES2 (0.61) | NPC1RAB9AGSK3BMEN1KMT2A | |
| SCHEMBL3672574 | 0.83 | POLB (0.57) | GSK3BMEN1KMT2APOLBMAPT | |
| SCHEMBL6159093 | 0.82 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2GSK3BMEN1 | |
| SCHEMBL20491340 | 0.82 | GAA (0.53) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL28021892 | 0.81 | MAPT (0.54) | GSK3BMEN1KMT2AMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124204-A1 | METALLOENZYME INHIBITOR COMPOUNDS | EIKONIZO THERAPEUTICS, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12370194-B2 | Metalloenzyme inhibitor compounds | EIKONIZO THERAPEUTICS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20240307391-A1 | METALLOENZYME INHIBITOR COMPOUNDS | EIKONIZO THERAPEUTICS, INC. (US) | 2024-09-19 | — | — | US | disclosed |
| US-11938134-B2 | Metalloenzyme inhibitor compounds | EIKONIZO THERAPEUTICS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-20220088018-A1 | METALLOENZYME INHIBITOR COMPOUNDS | EIKONIZO THERAPEUTICS, INC. (US) | 2022-03-24 | — | — | US | disclosed |
| US-20200171028-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS HOLDINGS, LLC | 2020-06-04 | — | — | US | disclosed |
| US-10357493-B2 | Metalloenzyme inhibitor compounds | SELENITY THERAPEUTICS (BERMUDA), LTD. (BM) | 2019-07-23 | — | — | US | disclosed |
| US-20180256572-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VPS-3, INC. (US) | 2018-09-13 | — | — | US | disclosed |
| CN-100503562-C | Pyrrolidone derivatives as MAOB inhibitors | HOFFMANN LA ROCHE (CH) | 2009-06-24 | — | — | CN | disclosed |
| CN-1681777-A | Pyrrolidone derivatives as MAOB inhibitors | HOFFMANN LA ROCHE (CH) | 2005-10-12 | — | — | CN | disclosed |
| US-5571810-A | ANTIINFLAMMATORY AGENTS, ANALGESICS, COLLAGEN DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-11-05 | — | — | US | disclosed |
| EP-0593761-A1 | NEW THIOPHENE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-04-27 | — | — | EP | disclosed |
| WO-1991019708-A1 | NEW THIOPHENE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240307391-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC1, HDAC2 | NPC1 320/4885RAB9A 1505/4885SMN1; SMN2 447/4885 |
| US-20220088018-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC1, HDAC2 | NPC1 320/4885RAB9A 1505/4885SMN1; SMN2 447/4885 |
| US-20180256572-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC1, HDAC2 | NPC1 320/4885RAB9A 1505/4885SMN1; SMN2 447/4885 |
| US-20200171028-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC1, HDAC2 | NPC1 320/4885RAB9A 1505/4885SMN1; SMN2 447/4885 |
| US-20260124204-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC3, HDAC1 | NPC1 710/4885RAB9A 340/4885SMN1; SMN2 2245/4885 |
| US-11938134-B2 | Metalloenzyme inhibitor compounds | HDAC6, HDAC1, HDAC2 | NPC1 320/4885RAB9A 1505/4885SMN1; SMN2 447/4885 |
| US-10357493-B2 | Metalloenzyme inhibitor compounds | HDAC6, HDAC1, HDAC2 | NPC1 320/4885RAB9A 1505/4885SMN1; SMN2 447/4885 |
| US-12370194-B2 | Metalloenzyme inhibitor compounds | HDAC6, HDAC1, HDAC2 | NPC1 320/4885RAB9A 1505/4885SMN1; SMN2 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.